JW LIFESCIENCE revenue for the last year amounted to 222.50 B KRW, the most of which — 222.48 B KRW — came from its highest performing source at the moment, Intravenous Fluids, the year earlier bringing 206.86 B KRW. The greatest contribution to the revenue figure was made by South Korea — last year it brought JW LIFESCIENCE 222.48 B KRW, and the year before that — 206.86 B KRW.